🇺🇸 copper histidinate in United States

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FDA authorised copper histidinate on 12 January 2026

Marketing authorisation

FDA — authorised 12 January 2026

Application: NDA211241
Marketing authorisation holder: SENTYNL THERAPS INC
Local brand name: ZYCUBO
Indication: POWDER — SUBCUTANEOUS
Status: approved

Read official source →

Frequently asked questions

Is copper histidinate approved in United States?

Yes. FDA authorised it on 12 January 2026.

Who is the marketing authorisation holder for copper histidinate in United States?

SENTYNL THERAPS INC holds the US marketing authorisation.